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(57) ABSTRACT 
Methods and devices are provided for administering a drug to 
a patient's eye. The methods include (a) inserting a hollow 
microneedle into the sclera or corneal stroma without pen-
etrating across the sclera or corneal stroma; and (b) infusing 
a fluid drug formulation through the microneedle and into the 
sclera or cornea. It further may include partially retracting the 
microneedle before infusion to enhance delivery. Alterna-
tively, the methods may include (a) inserting a solid micron-
eedle into the sclera or corneal stroma without penetrating 
across the sclera or corneal stroma, wherein the solid micron-
eedle comprises a first quantity of a drug formulation and 
inserting causes the solid microneedle to form a pocket in the 
sclera or corneal stroma; and (b) releasing the drug formula-
tion into the pocket to form a drug depot, whereby a drug is 
released from the depot. The methods and devices may 
include an array of multiple microneedles. 
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METHOD FOR DRUG DELIVERY TO 
OCULAR TISSUE USING MICRONEEDLE 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit of U.S. Provisional Appli-
cation No. 60/746,237, filed May 2, 2006. The application is 
incorporated herein by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
2 
the sclera or cornea, wherein the fluid drug formulation com-
prises a drug. In a certain embodiment, this method further 
includes after the insertion step and before and/or during the 
step of infusing, partially retracting the at least one hollow 
microneedle from the sclera or corneal stroma. In a certain 
embodiment, the steps of inserting and retracting the at least 
one hollow microneedle form a pocket in the sclera or corneal 
stroma. 
The step of infusing may be performed after the step of 
10 partially retracting the at least one microneedle out of the 
sclera or corneal stroma. The step of infusing may include 
driving the fluid drug formulation using a pressure gradient or 
an electric field. 
This invention was made with U.S. govermnent support 
under Contract No. 8 ROI EB00260-03 and Contract No. 15 
The step ofinfusion may create a drug depot in the sclera or 
corneal stroma for sustained release of the drug from the drug 
depot after the step of infusion is completed. In certain 
embodiments, the drug from the drug depot may be delivered 
to choroidal or retinal tissues. In certain embodiments, the 
drug may be delivered to the ciliary body, the trabecular 
R24EY017045-01, which were awarded by the National 
Institute of Health. The U.S. government has certain rights in 
the invention. 
BACKGROUND OF THE INVENTION 
This invention is generally in the field of ophthalmic thera-
pies, and more particularly to the use of microneedles for 
local drug delivery to and/or diagnostic sensing in ocular 
tissues. 
The delivery of drug to the eye is extremely difficult, par-
ticularly delivery of macromolecules and delivery to the back 
of the eye. Many inflammatory and proliferative diseases in 
the posterior region of the eye require long term pharmaco-
logical treatment. Examples of such diseases include macular 
degeneration and diabetic retinopathy. It is difficult to deliver 
effective doses of drug to the back of the eye using conven-
tional delivery methods such as topical application, which has 
poor efficacy, and systemic administration, which often 
causes significant side effects. (Geroski & Edelhauser, Invest. 
Ophthalmol. Vis. Sci. 41:961-64 (2000)). For example, while 
eye drops are useful in treating conditions affecting the exte-
rior surface of the eye or tissues atthe front of the eye, the eye 
drops cam10t penetrate to the back of the eye, as may be 
required for the treatment of various retinal diseases. 
Direct injection into the eye, using conventional needles 
and syringes is often effective, but requires professional train-
ing and raises concerns about safety. (Maurice, J. Ocul Phar-
macol. Ther. 17:393-401 (2001 )). It also would be desirable to 
be able to minimize the number and/or frequency of eye 
injection treatments needed to effect delivery of a selected 
quantity of drug. 
It therefore would be desirable to provide better, safer, 
more effective techniques for the direct delivery of therapeu-
tic agents to eye tissues. It also would be desirable to provide 
devices useful in such techniques which can be relatively 
inexpensive to produce and use. It further would be desirable 
to provide methods for pinpoint delivery of drug to scleral or 
corneal tissues. 
SUMMARY OF THE INVENTION 
Methods are provided for administering a drug to an eye of 
a patient. The methods may be used, for example, in the 
treatment of uveitis, glaucoma, diabetic macular edema, age-
related macular degeneration, corneal infection, or cytome-
galovirus retinitis. 
In one aspect, a method is provided that includes the steps 
of (a) inserting at least one hollow microneedle into the sclera 
or corneal stroma of the eye without penetrating across the 
sclera or corneal stroma; and (b) infusing a fluid drug formu-
lation through the at least one hollow microneedle and into 
20 meshwork, the aqueous humor, or the vitreous humor. 
In a preferred embodiment, the method may include the use 
of an array of two or more microneedles. For example, the 
step of inserting may further comprise substantially simulta-
neously inserting a second hollow microneedle into the sclera 
25 or corneal stroma without penetrating across the sclera or 
corneal stroma, and the step of infusing may further comprise 
infusing the fluid drug formulation through the second hollow 
microneedle and into the sclera or corneal stroma. The at least 
one (i.e., first) hollow microneedle and the second hollow 
30 microneedle are part of a device having an array of two or 
more microneedles. 
In one embodiment the fluid drug formulation comprises a 
suspension of microparticles or nanoparticles for controlled 
release of the drug. In one embodiment, the fluid drug formu-
35 lation further includes an agent effective to degrade collagen 
or glycosaminoglycan (GAG) fibers in the sclera or corneal 
stroma. This agent may be, for example, an enzyme, such a 
hyaluronidase, a collagenase, or a combination thereof. 
In another aspect, a method is provided that includes the 
40 steps of (a) inserting at least one solid microneedle into the 
sclera or corneal stroma of the eye without penetrating across 
the sclera or corneal stroma, wherein the at least one solid 
microneedle comprises a first quantity of a drug formulation 
and the step of inserting causes the at least one solid micron-
45 eedle to form a pocket in the sclera or corneal stroma; and (b) 
releasing at least part of the first quantity of the drug formu-
lation into the pocket to form a drug depot in the sclera or 
corneal stroma, whereby a drug in the drug formulation sub-
sequently is released from the drug depot. In one embodi-
50 ment, the method may include driving the drug into or 
through the sclera or corneal stroma using an electric field or 
acoustic energy. In certain embodiments, the drug from the 
drug depot may be delivered to choroidal or retinal tissues. In 
certain embodiments, the drug may be delivered to posterior 
55 chamber tissue or to anterior chamber tissue. 
In a preferred embodiment, the method may include the use 
of an array of two or more microneedles. For example, the 
step of inserting may further comprise substantially simulta-
neously inserting a second solid microneedle into the sclera 
60 or corneal stroma without penetrating across the sclera or 
corneal stroma, wherein (i) the second solid microneedle 
includes a second quantity of the drug formulation, and (ii) 
the step of inserting causes the second solid microneedle to 
form a second pocket in the sclera or corneal stroma; and the 
65 step ofreleasing further includes releasing the second quan-
tity of the drug formulation into the second pocket to form a 
second drug depot in the sclera or corneal stroma, whereby 
US 7,918,814 B2 
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subsequently the drug is released from the second drug depot 
into the eye. The at least one (i.e., first) solidmicroneedle and 
the second solid microneedle are part of a device having an 
array of two or more microneedles. 
In a preferred embodiment, the method further includes 
completely withdrawing the at least one solid microneedle 
from the sclera or corneal stroma after the step of inserting, 
wherein the drug depot provides sustained release of the drug 
after the at least one solid microneedle has been completely 
withdrawn. 10 
4 
In one embodiment with hollow microneedles, the means 
for depositing comprises a fluid drug formulation, a source 
reservoir for the fluid drug formulation, and an infusion 
means for driving the fluid drug formulation from the source 
reservoir into the pocket. In a certain embodiment, the infu-
sion means may include a pump or syringe. In a preferred 
embodiment, the fluid drug formulation comprises a suspen-
sion of microparticles or nanoparticles which comprise a drug 
for controlled release. 
In one embodiment, the portion of the microneedle that is 
designed to insert into the sclera or corneal stoma has a 
maximum cross-sectional width or diameter between 50 
microns and 400 microns. In one embodiment, the portion of 
the microneedle that is designed to insert into the sclera or 
corneal stoma has length between 50 microns and 1000 
microns. 
In one particular embodiment, a microneedle device is 
provided for delivery of a drug to the eye that includes at least 
one solid microneedle extending from a base; means for 
In one embodiment, the at least one solid microneedle 
comprises a solid or semi-solid coating that includes the drug 
formulation. In one case, the step of releasing comprises at 
least partially dissolving the coating off of the at least one 
15 
solid microneedle into fluids present in the sclera or corneal 
stroma. In another embodiment, the step of releasing includes 
breaking or dissolving all or part of the at least one solid 
microneedle off of a base to which the at least one solid 
microneedle is connected prior to said breaking or dissolving. 20 controllably inserting the at least one solid microneedle into 
the sclera or corneal stroma without penetrating across the 
sclera or corneal stroma; and a drug formulation which com-
prises a drug, wherein the device is adapted to deposit the 
drug formulation into the sclera or corneal stroma to form a 
In this case, the drug formulation is broken off or dissolves off 
with or as part of the microneedle. In these embodiments of 
the method, the drug formulation may include microparticles 
or nanoparticles which comprise a drug for controlled rel ease. 
In one embodiment, the hollow or solid microneedle is 
rotated or vibrated during the step of inserting. In another 
embodiment, the hollow or solid microneedle is inserted into 
the surface of the sclera or corneal stroma at an angle of about 
25 drug depot for controlled release of the drug to an ocular 
90 degrees. 
tissue. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA, lB, and lC are cross-sectional illustrations of 
the tissue structures of a human eye. The eye as a whole (lA), 
a close-up of the cornea (lB), anda close-up of the sclera and 
associated tissues (lC) are shown. 
FIG. 2 is a cross-sectional view of a solid microneedle 
In another aspect, a method of extraction from a tissue of 30 
the eye is provided that includes the steps of (a) inserting at 
least one microneedle into the sclera or corneal stroma, with-
out penetrating across the sclera or corneal stroma; and (b) 
withdrawing a biological fluid, tissue, or molecule sample 
from the sclera or corneal stroma with the at least one micron-
eedle. 
35 having a drug-comprising coating, according to one embodi-
ment. 
In yet another aspect, a microneedle device is provided for 
delivery of a drug to the eye. In one embodiment, the device 
includes an array of two or more microneedles extending 
from a base; means for controllably inserting the two or more 40 
microneedles into the sclera or corneal stroma without pen-
etrating across the sclera or corneal stroma; and means for 
depositing a drug formulation in the sclera or corneal stroma 
to form a drug depot for subsequent release to an ocular tissue. 
In certain embodiments, the two or more microneedles 45 
may be hollow or solid. In various embodiments, the hollow 
or solid microneedle may be made of metal or a polymer. 
In one embodiment, the drug depot provides extended or 
sustained release of a drug. In one embodiment, the drug 
formulation comprises microparticles or nanoparticles which 50 
provide controlled release of the drug. 
The means for depositing may include a coating on the two 
or more microneedles, wherein the coating comprises the 
drug formulation. In one embodiment, the coating may be 
solid or semi-solid. The coating may be at least partially 55 
soluble in fluids present in the sclera or corneal stroma. In 
another embodiment, all or part of the two or more micron-
eedles are adapted to break or dissolve off of the base in the 
sclera or cornea. 
In one embodiment, the two or more microneedles extend 60 
from the base at an angle of about 90 degrees to provide 
approximately perpendicular insertion of the microneedles 
into the surface of the sclera or corneal stroma. In one 
embodiment, the base has either a fixed radius of curvature 
substantially the same as the radius of curvature of surface of 65 
a sclera or corneal stroma, or is elastically deformable to fit 
the radius of curvature of surface of a sclera or corneal stroma. 
FIG. 3 is a cross-sectional view of a hollow microneedle 
according to one embodiment. 
FIG. 4 is a cross-sectional view of an array of solidmicron-
eedles according to one embodiment. 
FIGS. SA and SB illustrate an embodiment of a process for 
using a hollow microneedle to deliver drug into the corneal 
stroma of an eye, where the process includes partial retraction 
of the hollow microneedle and infusion of a fluid drug for-
mulation. 
FIGS. 6A and 6B illustrate an embodiment of a process for 
inserting a solid microneedle which has a drug formulation 
coating, into the sclera of an eye. 
FIGS. 7A and 7B are brightfield microscopic images of 
histological sections of human sclera pierced with a solid 
microneedle and subsequently stained with a blue tissue 
marking dye and for a sulforhadamine-coated microneedle, 
respectively. 
FIGS. SA and SB illustrate the fluorescein concentration 
profiles in a rabbit eye over time as an average value in the 
aqueous humor as a comparison of microneedle (gray bars) 
and topical delivery (black bars), respectively. 
FIG. 9 is a graph showing the changes in the pupil diameter 
ofa rabbit over a time for an untreated eye and for eyes treated 
with pilocarpine coated microneedles or topical applications 
of pilocarpine. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
In one aspect of the invention, microneedle devices and 
methods of use have been developed to enhance the delivery 
US 7,918,814 B2 
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of a drug to the eye, enabling drug to be locally administered 
6 
a clear membrane referred to as the conjunctiva (not shown). 
Underlying the sclera 20 is the choroid 28 and the retina 27. 
FIG. lB illustrates the cornea 16, which is composed of the 
epithelium 30, the Bowman's layer 32, the stroma 34, the 
Descemet's membrane 36, and the endothelium 38. FIG. lC 
illustrates the sclera 20 with surrounding Tenon's Capsule 40 
or conjunctiva 41, choroid 28, and retina 27. 
The method of administering a drug to the eye generally 
comprises the steps of inserting a microneedle into the ocular 
in useful quantities. In one advantageous and exemplary 
embodiment of the methods described herein, sustained 
delivery of a drug is achieved from a drug depot created in the 
sclera or cornea with the microneedle and a drug formulation. 
The microneedle is able to precisely locate the drug in the 
sclera or corneal tissue for subsequent local delivery to 
nearby tissues in need of treatment. The drug may be released 
for an extended period, e.g., several hours, after the micron-
eedle has been inserted and withdrawn, providing increased 
bioavailability of the drug relative, for example, to delivery by 
topical application of the drug formulation to ocular tissue 
surfaces. The method advantageously includes precise con-
trol of the depth of insertion into the ocular tissue, so that the 
microneedles do not cross into the anterior chamber underly-
ing the cornea or penetrate across the sclera to contact under-
lying tissue layers, such as choroid andretina tissues. Micron-
eedles enable this to be done in a minimally invasive manner. 
10 tissue and depositing a drug formulation into the ocular tis-
sue. In a particular embodiment, at least one microneedle is 
inserted into the sclera or corneal stroma of the eye without 
penetrating across the scleral or corneal stroma. In one 
embodiment, which may be particularly useful with hollow 
15 microneedles, the method of administering a drug to the eye 
may further include partially retracting the hollow micron-
eedle after the insertion step and before and/or during the 
depositing of the drug formulation. 
In a particular embodiment, the partial retraction of the Advantageously, an array of microneedles may be pro-
vided so that multiple drug depots can be deposited in the 
sclera or cornea with a single application/treatment. More-
over, the spacing of the microneedles in the array beneficially 
can "spread" the delivery of drug over a larger tissue area in a 
single administration as compared to a single administration 
using previously known single needle devices. It may be 
important to minimize the distance the drug must diffuse from 
the depot to reach tissues in need of treatment. It would be 
advantageous to accomplish the treatment with as few injec-
tion events as possible. 
20 microneedle occurs prior to the step of infusing the fluid drug 
formulation into the ocular tissue. This insertion/retraction 
step forms a pocket and beneficially permits the fluid drug 
formulation to flow out of the microneedle unimpeded or less 
impeded by ocular tissue at the opening at the tip portion of 
25 the microneedle. FIG. SA shows a hollow microneedle 130 
As used herein, the terms "comprise," "comprising," 30 
"include," and "including" are intended to be open, non-
limiting terms, unless the contrary is expressly indicated. 
Methods of Using the Microneedle 
The microneedle devices described herein may be used to 
deliver drug formulations to the eye, particularly for the treat- 35 
ment, diagnosis, or prevention of ocular diseases. A wide 
range of ocular diseases and disorders may be treated by the 
methods and devices described herein. Non-limiting 
examples of ocular diseases include uveitis, glaucoma, dia-
betic macular edema or retinopathy, macular degeneration, 40 
corneal infection, cytomegalovirus retinitis, and dry eye (i.e., 
keratoconjunctivitis sicca). 
The microneedles can be used to target delivery to specific 
tissues or regions within the eye. For example, targeted deliv-
ery to the anterior chamber of the eye may be achieved by 45 
microneedle delivery of a drug formulation into the cornea. 
As another example, targeted delivery to the posterior seg-
ment may be achieved by microneedle delivery of a drug 
formulation to the sclera. Injection may be performed rela-
tively quickly, e.g., in less than one minute, and possibly 50 
facilitated by having the patient look all the way to the left or 
right and then inserting microneedles at, or posterior to, the 
equator. In various embodiments, the methods may be 
designed for drug delivery specifically to the ciliary body, the 
trabecular meshwork, the aqueous humor, or the vitreous 55 
humor. 
inserted into the corneal stroma 34, with drug formulation 
131 temporarily positioned in the hollow bore of the micron-
eedle. (The fluid communication to a reservoir of the fluid 
drug formulation is not shown.) FIG. SB shows the micron-
eedle 130 following partial retraction to form pocket lSO and 
infusion of fluid drug formulation 131 therein. Arrows show 
further transport of the drug formulation into the tissue. 
The microneedle optionally may be part of an array of two 
or more microneedles such that the method further includes 
inserting at least a second microneedle into the sclera or 
corneal stroma without penetrating across the sclera or cor-
neal stroma. The method of inserting the microneedle and/or 
depositing a drug formulation optionally may include rotat-
ing the microneedle or vibrating the microneedle during the 
insertion step or the release step, or during both steps. 
Importantly, the depth of insertion into the ocular tissue is 
precisely controlled. In one preferred embodiment, the one or 
more microneedles are inserted within the cornea, neither 
across nor entering the anterior chamber. In another preferred 
embodiment, the one or more microneedles are inserted 
within the sclera without penetration/contacting underlying 
tissue layers, such as choroid and retina tissues. (The drug 
depot formed using the microneedle and drug formulation 
can, however, deliver drug to these underlying tissues.) 
Essentially any method can be used to control the insertion 
depth. In one embodiment, the microneedles are designed to 
have a length approximately equal to the desired penetration 
depth. In another embodiment, the microneedles are designed 
to have a length longer than the desired penetration depth, but 
the microneedles are controllably inserted only part way into 
the tissue. Partial insertion may be controlled by the mechani-
cal properties of the tissue, which bends and dimples during 
the microneedle insertion process. In this way, as a micron-
eedle is inserted into the tissue, its movement partially elas-
As used herein, "ocular tissue" and "eye" 10 include both 
the anterior segment 12 of the eye (i.e., the portion of the eye 
in front of the lens) and the posterior segment 14 of the eye 
(i.e., the portion of the eye behind the lens), as illustrated in 
FIG. lA. The anterior segment 12 is bounded by the cornea 16 
and the lens 18, while the posterior segment 14 is bounded by 
the sclera 20 and the lens 18. The anterior segment 12 is 
further subdivided into the anterior chamber 22, between the 
iris 24 and the cornea 16, and the posterior chamber 26, 
between the lens 18 and the iris 24. The exposed portionofthe 
sclera 20 on the anterior segment 12 of the eye is protected by 
60 tically deforms the tissue and partially penetrates into the 
tissue. By controlling the degree to which the tissue deforms, 
the depth of microneedle insertion into the tissue can be 
controlled. In another embodiment, a microneedle is inserted 
into the tissue using a rotational/drilling technique and/or a 
65 vibrating action. In this way, the microneedle can be inserted 
to a desired depth by, for example, drilling the microneedles 
a desired number of rotations, which corresponds to a desired 
US 7,918,814 B2 
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depth into the tissue. See, e.g., U.S. Patent Application Pub-
lication No. 20050137525 Al to Wang et al., which is incor-
porated herein by reference, for a description of drilling 
microneedles. 
The amount of drug delivered within the ocular tissue may 
be controlled, in part, by the type of microneedle used and 
how it is used. In one exemplary embodiment, a hollow 
microneedle is inserted into the ocular tissue and progres-
sively retracted from the ocular tissue after insertion to deliver 
a fluid drug, where after achieving a certain dosage, the deliv-
ery could be stopped by deactivating the fluid driving force, 
such as pressure (e.g., from a mechanical device such as a 
syringe) or an electric field, to avoid leakage/uncontrolled 
deliver of drug. 
Methods of depositing or releasing the drug formulation 
into ocular tissue during microneedle insertion may occur in 
different ways, depending for example on whether the 
microneedle is solid or hollow. The methods may include (a) 
infusing a fluid drug formulation through a hollow micron-
eedle (e.g., driving the drug formulation from a source reser-
voir into the ocular tissue by a pressure gradient (e.g., pump-
ing, syringe) or an electric field (e.g., iontophoresis) or 
another externally applied energy (e.g., ultrasound/acoustic 
energy), (b) dissolving, at least in part, a coating of a drug 
formulation off of a solid (or hollow) microneedle, ( c) detach-
ing, at least in part, a coating of a drug formulation (e.g., as a 
substantially intact sleeve or in fragments) off of a solid (or 
hollow) microneedle, (d) breaking or dissolving a solid (or 
hollow) microneedle off of a base to which the microneedle is 
integrally formed or is connected), or ( e) a combination of (a) 
through ( d). 
FIG. 6A shows solid microneedle 110 with drug formula-
tion coating 161 inserted into the sclera 20. FIG. 6B shows the 
microneedle 110 following complete withdrawal of the 
microneedle 110 from the tissue, to form pocket 160 into 
which the drug formulation has been released from the 
microneedle and deposited to form a drug depot 162 from 
which the drug subsequently is released (as shown by arrows 
from the depot). 
In a particular embodiment, the microneedle deposits a 
drug formulation within the cornea or sclera for controlled 
(i.e., sustained or extended) release of a drug to one or more 
ocular tissues surrounding the depot. This "sustained release" 
8 
ocular tissue, and releasing of the second drug formulation 
into or through the second pocket will form a second drug 
depot from which the second drug formulation subsequently 
may be released. 
In one embodiment, the drug formulation for delivery into 
the eye is in the form of or includes polymeric nanoparticles 
or microparticles encapsulating the active agent. Nanopar-
ticle or microparticle encapsulation techniques are well 
known in the art. In another embodiment, the drug formula-
lO tion is one which undergoes a phase change upon adminis-
tration. For instance, a liquid drug formulation may be 
injected through hollow microneedles into the ocular tissue, 
where it then gels within the ocular tissue and the drug dif-
15 fuses out from the gel for controlled release. 
In another embodiment, the microneedle is formed of a 
drug encapsulated within a polymer, which can be implanted 
into the ocular tissue for drug release upon degradation/dis-
solution of the microneedle. The polymer may be a biode-
20 gradable one, such as poly(lactide-co-glycolide) (PLGA). In 
a specific case, the microneedle or the tip portion thereof may 
be intentionally broken off in the sclera or cornea, and sub-
sequently will biodegrade and release drug. 
In still another embodiment, the microneedle is formed of 
25 metal and coated with a drug formulation, which delivers the 
drug by dissolution/diffusion upon insertion into the ocular 
tissue. In a particular embodiment, the drug coating is soluble 
in the fluids present in the ocular tissue, but is designed to 
have a dissolution rate that is sufficiently slow to avoid dis-
30 solution in the tear film during insertion of the microneedle 
device, thereby preventing excess/premature loss of drug. 
The microneedle devices described herein also may be 
used to remove substances, such as a fluid, tissue, or molecule 
35 
sample, from the eye. For example, the microneedle may be 
used to remove intraocular fluid from the eye to treat glau-
coma. The fluid may be withdrawn through a hollow micron-
eedle while the microneedle remains in an inserted position in 
the ocular tissue. Alternatively, the fluid may flow out through 
40 an aperture left in the ocular tissue after the solid or hollow 
microneedle has been withdrawn from the tissue. Tissue may 
be removed by a coring method related to conventional biop-
sies. Molecules may be removed by binding a molecule to the 
microneedle. The binding may be a selective chemical bind-
ing. 
The microneedle devices described herein also may be 
adapted to use the one or more microneedles as a sensor to 
detect analytes, electrical activity, and optical or other sig-
nals. The sensor may include sensors of pressure, tempera-
or "extended release" is generally more prolonged than that 
obtainable by topical application of the drug formulation to 45 
the ocular tissue. In a particular embodiment, the drug depot 
provides extended or sustained release of the drug formula-
tion after the at least one microneedle is withdrawn from the 
ocular tissue. This delivery method can be particularly advan-
tageous with ocular tissues, where it is desirable for the inser-
tion and withdrawal process to occur over as short a period as 
possible to minimize patient discomfort-in contrast to trans-
dermal microneedle patch applications, where patches may 
more likely be worn (with microneedles inserted) over an 
extended period without patient discomfort. 
50 ture, chemicals, and/or electromagnetic fields (e.g., light). 
Biosensors can be located on the microneedle surface, inside 
a hollow or porous microneedle, or inside a device in com-
munication with the body tissue via the microneedle (solid, 
hollow, or porous). The microneedle biosensor can be any of 
55 the four classes of principal transducers: potentiometric, 
amperometric, optical, and physiochemical. In one embodi-
ment, a hollow microneedle is filled with a substance, such as 
a gel, that has a sensing functionality associated with it. In an 
application for sensing based on binding to a substrate or 
In a preferred embodiment wherein an array of two or more 
microneedles are inserted into the ocular tissue, each micron-
eedle may form an independent pocket in the ocular tissue 
into or through which a drug formulation may be deposited. 
60 reaction mediated by an enzyme, the substrate or enzyme can 
be immobilized in the needle interior. In another embodi-
In a particular embodiment, the drug formulation of each of 
the two or more microneedles may be identical to or different 
from one another, in drug, formulation, volume/quantity of 
drug formulation, or a combination of these parameters. In 
one case, different types of drug formulations may be depos-
ited into the two or more pockets. For example, inserting a 65 
second solid microneedle comprising a second drug formu-
lation into the ocular tissue will form a second pocket in the 
ment, a wave guide can be incorporated into the microneedle 
device to direct light to a specific location, or for detection, for 
example, using means such as a pH dye for color evaluation. 
Similarly, heat, electricity, light or other energy forms may be 
precisely transmitted to directly stimulate, damage, or heal a 
specific tissue or for diagnostic purposes. 
US 7,918,814 B2 
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The Microneedle Device 
In an exemplary embodiment, the microneedle device 
includes a base from which one or more microneedles extend, 
typically in a direction normal (i.e., perpendicular) to the 
base. The microneedle can be hollow or solid. As used herein, 
the term "hollow" includes a single, straight bore through the 
center of the microneedle, as well as multiple bores, bores that 
follow complex paths through the microneedles, multiple 
entry and exit points from the bore( s ), and intersecting or 
networks of bores. That is, a hollow microneedle has a struc- 10 
tures that includes one or more continuous pathways from the 
base of the microneedle to an exit point in the shaft and/or tip 
portion of the microneedle distal to the base. The microneedle 
structure can be porous or non-porous. Drug can be coated 
onto themicroneedle; integrated into the structure of, or pores 15 
in, the microneedle; passed through bores/apertures or chan-
nels in the microneedle, or a combination thereof. The base 
may be substantially planar or it may be curved, for example, 
in the shape of the ocular tissue surface at the site of injection. 
The base may be rigid, or in a preferred embodiment flexible 20 
to conform to the shape of the ocular tissue at the site for 
injection. 
10 
or the cross-section can be non-circular. The tip portion of the 
microneedles can have a variety of configurations. The tip of 
the microneedle can be symmetrical or asymmetrical about 
the longitudinal axis of the shaft. The tips may be beveled, 
tapered, squared-off or rounded. The tip portion generally has 
a length that is less than 50% of the total length of the micron-
eedle. 
The dimensions of the microneedle, or array thereof, are 
designed for the particular way in which it is to be used. The 
length typically is selected taking into account both the por-
tion that would be inserted into the ocular tissue and the (base) 
portion that would remain uninserted. The cross-section, or 
width, is tailored to provide, among other things, the 
mechanical strength to remain intact for the delivery of the 
drug or for serving as a conduit for the withdrawal of biologi-
cal fluid, while being inserted into the skin, while remaining 
in place during its functional period, and while being 
removed (unless designed to break off, dissolve, or otherwise 
not be removed). In various embodiments, the microneedle 
may have a length of about 50 µm to about 2000 µm. In 
another particular embodiment, the microneedle may have a 
length of about 150 µm to about 2000 µm, about 300 µm to 
about 2000 µm, about 300 µm to about 1500 µm, about 300 
µm to about 1000 µm, or about 300 to about 750 µm. In one 
FIGS. 2 and 3 illustrate two exemplary embodiments of the 
microneedle devices. In one embodiment, illustrated in FIG. 
2, the microneedle device 110 includes a base 112 and a solid 
microneedle 114, which is coated with a drug formulation 
120. The solid microneedle 114 includes a proximal portion 
116 and a tip portion 118. In another embodiment, illustrated 
25 embodiment, the length of the microneedle is about 500 µm. 
in FIG. 3, the microneedle device 130 includes a base 132 and 
In various embodiments, the base portion of the microneedle 
has a maximum width or cross-sectional dimension of about 
20 µm to about 500 µm, about 50 µm to about 400 µm, or about 
100 µm to about 250 µm. For a hollow microneedle, the 
a hollow microneedle 134 which has a bore 140 through 
which a fluid drug formulation (not shown) can be delivered 
30 maximum outer diameter or width may be about 50 µm to 
about 400 µm, with an aperture diameter of about 5 µm to 
about 100 µm. The microneedle may be fabricated to have an 
aspect ratio (width:length) of about 1:1.5 to about 11:10. 
to the eye or through which a biological fluid can be with-
drawn from the eye. The hollow microneedle 134 includes a 
proximal portion 136 and a tip portion 138. FIG. 4 illustrates 
one possible embodiment of a microneedle array device 140, 35 
which includes a base 142 from which solid microneedles 
144 (five are shown) extend. 
Other lengths, widths, and aspect ratios are envisioned. 
In various embodiments, the microneedle device includes a 
single microneedle or an array of two or more microneedles. 
For example, the device may include an array of between 2 
and 1000 (e.g., between 2 and 100) microneedles. In one 
embodiment, a device may include between 2 and 10 micron-
40 eedles. An array of microneedles may include a mixture of 
different microneedles. For instance, an array may include 
microneedles having various lengths, base portion diameters, 
tip portion shapes, spacings between microneedles, drug 
The microneedle can be formed/constructed of different 
biocompatible materials, including metals, glasses, semi-
conductor materials, ceramics, or polymers. Examples of 
suitable metals include pharmaceutical grade stainless steel, 
gold, titanium, nickel, iron, gold, tin, chromium, copper, and 
alloys thereof. The polymer can be biodegradable or non-
biodegradable. Examples of suitable biocompatible, biode-
gradable polymers include polylactides, polyglycolides, 45 
polylactide-co-glycolides (PLGA), polyanhydrides, poly-
orthoesters, polyetheresters, polycaprolactones, polyestera-
mides, poly(butyric acid), poly(valeric acid), polyurethanes 
and copolymers and blends thereof. Representative non-bio-
degradable polymers include polyacrylates, polymers of eth- 50 
ylene-vinyl acetates and other acyl substituted cellulose 
acetates, non-degradable polyurethanes, polystyrenes, poly-
vinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), 
chlorosulphonate polyolefins, polyethylene oxide, blends 
and copolymers thereof. Biodegradable microneedles can 55 
provide an increased level of safety compared to non-biode-
gradable ones, such that they are essentially harmless even if 
inadvertently broken off into the ocular tissue. This applies 
whether the microneedles contain molecules for delivery or 
serve merely a conduit function. 
The microneedle can have a straight or tapered shaft. In one 
embodiment, the diameter of the microneedle is greatest at 
the base end of the microneedle and tapers to a point at the end 
distal the base. The microneedle can also be fabricated to have 
60 
a shaft that includes both a straight (i.e., untapered) portion 65 
and a tapered portion. The microneedles can be formed with 
shafts that have a circular cross-section in the perpendicular, 
coatings, etc. 
The single microneedle or array of two or more micron-
eedles may extend from the base of the microneedle device at 
any angle suitable for insertion into the eye. In a particular 
embodiment, the single microneedle or array of two or more 
microneedles extend from the base at an angle of about 90 
degrees to provide approximately perpendicular insertion of 
the microneedles into the surface of the eye. In another par-
ticular embodiment, the single microneedle or array of two or 
more microneedles extend from the base at an angle from 
about 60 to about 90 degrees. In embodiments wherein the 
microneedle device comprises an array of two or more 
microneedles, the angle a single microneedle extends from 
the base may be independent from the angles at which the 
other microneedles in the array extend from the base of the 
device. 
The microneedle can be fabricated by a variety of methods 
known in the art or as described in the Examples below. 
Details of possible manufacturing techniques are described, 
for example, in U.S. PatentApplicationPublicationNo. 2006/ 
0086689 Al to Raju et al., U.S. Patent Application Publica-
tion No. 2006/0084942 to Kim et al., U.S. Patent Application 
Publication No. 2005/0209565 to Yuzhakov et al., U.S. Patent 
Application Publication No. 2002/0082543 Al to Park et al., 
US 7,918,814 B2 
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U.S. Pat. No. 6,334,856 to Allen et al., U.S. Pat. No. 6,6I I, 
707 to Prausnitz et al., U.S. Pat. No. 6,743,2I I to Prausnitz et 
al., all of which are incorporated herein by reference for their 
disclosure of microneedle fabrication techniques. 
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and cycloplegics, mitomycin C, and collagenase inhibitors 
and treatments of age-related macular degeneration such as 
pegagtanib sodium, ranibizumab, and bevacizumab. 
In certain embodiments the drug may be an integrin 
antagonist, a selectin antagonist, an adhesion molecule 
antagonist (e.g., Intercellular Adhesion Molecule (ICAM)- I, 
ICAM-2, ICAM-3, Platelet Endothelial Adhesion Molecule 
(PCAM), Vascular Cell Adhesion Molecule (VCAM)), or a 
leukocyte adhesion-inducing cytokine or growth factor 
In a particular embodiment, microneedles would be fabri-
cated on a flexible base substrate. Because the surface of the 
eye is curved, it would be advantageous in some circum-
stances to have a base substrate that can bend to conform to 
the shape of the ocular surface. In another particular embodi-
ment, the microneedles are fabricated on a curved base sub-
strate. The curvature of the base substrate would be designed 
to conform to the shape of the ocular surface, such that the 
base substrate would have a radius of curvature substantially 
the same as the radius of curvature of an ocular tissue surface 
(e.g., sclera or cornea). For instance, the base substrate may 
have a radius of curvature between about 0.3 cm and about 0.9 
cm, e.g., between 0.5 cm and 0.7 cm. In such an embodiment, 
the base substrate can serve as a means for controlling the 
depth and angle of microneedle insertion. 
10 antagonist (e.g., Tumor Neucrosis Factor-a (TNF-a), Inter-
leukin-I~ (IL-I~), Monocyte Chemotatic Protein-I (MCP-I) 
and a Vascular Endothelial Growth Factor (VEGF)), as 
described in U.S. Pat. No. 6,524,58I to Adamis. In certain 
other embodiments, the drug may be sub-immunoglobulin 
15 antigen-binding molecules, such as Fv immunoglobulin frag-
ments, minibodies, and the like, as described in U.S. Pat. No. 
6, 773,9 I 6 to Thiel et al. In another embodiment, the drug may 
be a diagnostic agent, such as a contrast agent, known in the 
art. 
The drug typically needs to be formulated for storage and 
delivery via the microneedle device described herein. The 
"drug formulation" is a formulation of a drug, which typically 
includes one or more pharmaceutically acceptable excipient 
materials known in the art. The term "excipient" refers to any 
In another particular embodiment, the microneedles may 20 
be fabricated such that all or part of the microneedles are 
adapted to break or dissolve off of the base upon after inser-
tion into the ocular tissue. For example, the microneedle 
could be designed with one or more stress concentration 
regions (condition in which a stress distribution has high 
localized stresses, usually induced by an abrupt change in the 
shape, e.g., in the vicinity of notches, holes, changes in diam-
eter of a shaft, and so forth) or made brittle at a select location 
25 non-active ingredient of the formulation intended to facilitate 
handling, stability, dispersibility, wettability, release kinetics, 
and/or injection of the drug. The excipient may comprise, for 
example, a polymer, a protein, an amino acid, a sugar or other 
carbohydrate, a starch, a lipid, or a combination thereof. The in the microneedle. Alternatively, the microneedle may be 
fabricated with two or more materials that have different 
physical or chemical properties that can facilitate failure in 
vivo., e.g., by dissolution, water uptake/softening, chemical 
reaction, or the like. 
Drug and Drug Formulation 
30 drug formulation may be, for example, a liquid solution, a 
liquid suspension, a gel, or in solid (particulate or monolithic) 
form. The drug formulation can be tailored to flow through 
hollow microneedles from a reservoir, can be coated onto the 
microneedle, can be included/integrated into the microneedle 
35 structure, or a combination thereof. A wide range of drugs may be formulated for delivery to 
ocular tissues with the present microneedle devices and meth-
ods. As used herein, the term "drug" refers to essentially any 
prophylactic, therapeutic, or diagnostic agent, i.e., an ingre-
dient useful for medical, veterinary, or cosmetic applications. 
The drug may be selected from suitable proteins, peptides and 
fragments thereof, which can be naturally occurring, synthe-
sized or recombinantly produced. The drug may be an 
aptamer. Representative examples of types of drugs for deliv-
ery to ocular tissues include antibiotics, antiviral agents, anal-
gesics, anesthetics, antihistamines, anti-inflammatory agents, 45 
and antineoplastic agents. Non-limiting examples of specific 
drugs and classes of drugs include ~-adrenoceptor antago-
nists (e.g., carteolol, cetamolol, betaxolol, levobunolol, 
metipranolol, timolol), miotics (e.g., pilocarpine, carbachol, 
physostigmine), sympathomimetics (e.g., adrenaline, dipiv-
efrine ), carbonic anhydrase inhibitors (e.g., acetazolamide, 
dorzolamide), prostaglandins, anti-microbial compounds, 
including anti-bacterials and anti-fungals (e.g., chloram-
phenicol, chlortetracycline, ciprofloxacin, framycetin, 
fusidic acid, gentamicin, neomycin, norfloxacin, ofloxacin, 55 
polymyxin, propamidine, tetracycline, tobramycin, quino-
lines ), anti-viral compounds (e.g., acyclovir, cidofovir, 
idoxuridine, interferons), al dose reductase inhibitors, anti-
inflammatory and/or anti-allergy compounds (e.g., steroidal 
compounds such as betamethasone, clobetasone, dexametha- 60 
sane, fluorometholone, hydrocortisone, prednisolone and 
non-steroidal compounds such as antazoline, bromfenac, 
diclofenac, indomethacin, lodoxamide, saprofen, sodium 
cromoglycate), artificial tear/dry eye therapies, local anes-
thetics (e.g., amethocaine, lignocaine, oxbuprocaine, 65 
proxymetacaine ), cyclosporine, diclofenac, urogastrone and 
growth factors such as epidermal growth factor, mydriatics 
In one embodiment, the drug formulation includes micro-
particles or nanoparticles of drug suspended in an aqueous or 
non-aqueous liquid vehicle. The liquid vehicle may be a 
pharmaceutically acceptable aqueous solution, and option-
40 ally may further include a polymer and/or a surfactant. The 
microparticles or nanoparticles of drug themselves may 
include an excipient material, such as a polymer, a polysac-
charide, a surfactant, etc., which are known in the art to 
control the kinetics of drug release from particles. 
In one embodiment, the fluid drug formulation further 
includes an agent effective to degrade collagen or GAG fibers 
in the sclera or corneal stroma, which may enhance penetra-
tion/release of the drug into the ocular tissues. This agent may 
be, for example, an enzyme, such a hyaluronidase, a collage-
50 nase, or a combination thereof. In a variation of this method, 
the enzyme is administered to the ocular tissue in a separate 
step from-preceding or following-injection of administra-
tion of the drug. The enzyme and drug are administered at the 
same site. 
In one particular embodiment, the drug formulation may be 
coated onto microneedles by dip coating, spray coating, or 
other techniques known in the art, exemplary methods of 
which are describedinPCTPublicationNo. WO 2006I387I9 
A2 to Gill and Prausnitz, the disclosure of which is incorpo-
rated herein by reference in its entirety. Such coatings may be 
solid or semi-solid. In one embodiment, the coating may be at 
least partially soluble in the fluids present in the ocular tissue 
or may be adapted to detach from the microneedles in a 
substantially intact form. In another embodiment, the drug 
formulation may comprise a suspension of microparticles or 
nanoparticles for the controlled release of the drug as 
described herein. 
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Control Features for Directing Movement of the Microneedle 
in the Methods of Use 
The microneedle device may comprise a means for con-
trollably inserting, and optionally retracting, the microneedle 
into the ocular tissue. In addition, the microneedle device may 
include means of controlling the angle at which the at least 
one microneedle is inserted into the ocular tissue (e.g., by 
inserting the at least one microneedle into the surface of the 
ocular tissue at an angle of about 90 degrees). 
The depth of microneedle insertion into the ocular tissue 10 
can be controlled by the length of the microneedle, as well as 
other geometric features of the microneedle. For example, a 
flange or other a sudden change in microneedle width can be 
used to limit the depth of microneedle insertion. The micron-
eedle insertion can also be controlled using a mechanical 15 
micropositioning system involving gears or other mechanical 
components that move the microneedle into the ocular tissue 
14 
mechanically, or magnetically to selectively initiate, modu-
late, or stop the flow of material through the microneedles. In 
one embodiment, the flow is controlled with a rate-limiting 
membrane acting as the valve. 
The present invention may be further understood with ref-
erence to the following non-limiting examples. 
EXAMPLE 1 
Drug-Coated Solid Microneedles 
Single solid microneedles were fabricated using an infra-
red laser to cut microneedles from 75 micron thick stainless 
steel sheets. To deburr and sharpen the microneedle edges, 
electropolishing was done in a 1:3:6 v/v mixture of water: 
phosphoric acid:glycerine at 70° C. The final microneedle 
dimensions were 500 µm in length, 50x200 µm in cross 
section at the base, and 55° in tip angle. For in vivo rabbit 
experiments, the microneedles were modified to 500 µm in 
length, 50x 100 µmin cross section at the base, and 45° in tip 
angle, to avoid penetration through the thinner rabbit corneal 
tissue. To facilitate handling microneedles using forceps dur-
ing insertion into tissue, an extended metal substrate was 
attached to the needle base, which measured 1 cm in length, 4 
a controlled distance and, likewise, can be operated, for 
example, in reverse, to retract the microneedle a controlled 
distance. The depth of insertion can also be controlled by the 20 
velocity at which the microneedle is inserted into the ocular 
tissue. The retraction distance can be controlled by elastic 
recoil of the ocular tissue into which the microneedle is 
inserted or by including an elastic element within the micron-
eedle device that pulls the microneedle back a specified dis-
tance after the force of insertion is released. 
25 mm in width and 50 µm in thickness, was included in the 
needle design. 
The microneedles were coated at room temperature using a 
dip coating method and an aqueous coating solution. The 
aqueous coating solution contained 10% (w/v) poly-vinyl-
The angle of insertion can be directed by positioning the 
microneedle at a first angle relative to the microneedle base 
and positioning the base at a second angle relative to the 
ocular surface. In one embodiment, the first angle can be 
about 90° and the second angle can be about 0°. The angle of 
insertion can also be directed by having the microneedle 
protrude from a device housing through a channel in that 
housing that is oriented at a specified angle. 
30 pyrrolidone (1300 kDa) and 0.05% (w/v) sulforhodamine, 
1.0% (w/v) FITC-labeled bovine serum albumin, or 0.05% 
(w/v) YOY0-3-labeled gWiz luciferase plasmid DNA for in 
vitro experiments. The aqueous coating solution contained 
0.5% (w/v) sodium fluorescein and 10% (w/v) pilocarpine 
One skilled in the art may adapt mechanical systems 
known in the art in combination with the disclosure set forth 
herein and in the Examples below to devise suitable structures 
to controllably drive the microneedle insertion, which struc-
tures may be manually operable, electromechanically oper-
able, or a combination thereof. 
35 hydrochloride for in vivo experiments. The thickness of the 
coating was approximately 5 to 15 µm, and the dose coated 
onto the microneedles was measured by dissolving the coat-
ing into deionized water and measuring the compound con-
centration using fluorescence spectrometry or UV spectrom-
40 etry. 
Control of Transport Through Microneedle 
EXAMPLE2 
In Vitro Drug Delivery to Human Sciera 
Human sclera was obtained from the Georgia Eye Bank 
with the approval of the Georgia Tech IRB. Pieces of the 
scleral tissue were cut to a size of0.7x0.7 cm using surgical 
scissors and rinsed with deionized water. Adherent tissues 
The transport of drug formulation or biological fluid 
through a hollow microneedle can be controlled or monitored 
using, for example, one or more valves, pumps, sensors, 
actuators, and microprocessors. For instance, in one embodi- 45 
ment the microneedle device may include a micropump, 
microvalve, and positioner, with a microprocessor pro-
grammed to control a pump or valve to control the rate of 
delivery of a drug formulation through the microneedle and 
into the ocular tissue. The flow through a microneedle may be 
driven by diffusion, capillary action, a mechanical pump, 
electroosmosis, electrophoresis, convection or other driving 
forces. Devices and microneedle designs can be tailored 
using known pumps and other devices to utilize these drivers. 
50 associated with the retina, choroid, and episclera were 
removed from the scleral tissue with a cotton swab and the 
In one embodiment, the microneedle device may further 55 
include an iontophoretic apparatus, similar to that described 
in U.S. Pat. No. 6,319,240to Beck, for enhancing the delivery 
of the drug formulation to the ocular tissue. In another 
embodiment the microneedle devices can further include a 
flowmeter or other means to monitor flow through the 60 
microneedles and to coordinate use of the pumps and valves. 
scleral tissue was then placed on top of a hemispherical sur-
face (0.6 cm in radius), which simulated the curvature of the 
ocular surface. 
Uncoated single microneedles from Example 1 were 
manually inserted approximately half way into the sclera 
tissue and then removed. The insertion site was stained with a 
blue tissue dye and imaged by brightfield and fluorescence 
microscopy to assess the site and extent of delivery. 
The microneedles were found to be sufficiently strong and 
sharp to penetrate into the sci era without bending or breaking 
(data not shown). Within two minutes, the microneedle coat-
ing dissolved off and was deposited within the sclera, as 
shown in FIGS. 7 A-B. The figures also show that the insertion 
The flow of drug formulation or biological fluid can be 
regulated using various valves or gates known in the art. The 
valve may be one which can be selectively and repeatedly 
opened and closed, or it may be a single-use type, such as a 
fracturable barrier. Other valves or gates used in the micron-
eedle devices can be activated thermally, electrochemically, 
65 site penetrated approximately 300 µm deep into the sclera and 
that the coating was deposited throughout the microneedle 
hole, as well as some deposition along the sclera surface. 
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Coated microneedles from Example 1 then were tested to 
determine whether the coating remained intact during inser-
tion and rapidly dissolved off the microneedles within the 
tissue. The sodium fluorescein-coated microneedles from 
Example 1 were manually inserted into sclera tissue, left 
within the tissue for 20 seconds to allow the coating solution 
to dissolve off and then removed. The insertion site was 
stained with a blue tissue dye and imaged by brightfield and 
fluorescence microscopy to assess the site and extent of deliv-
ery (FIG. 7A). 
The sulforhodamine coating was found to be deposited to a 
large extent within the microneedle hole, showing that the 
coating was rapidly dissolved off the needle shaft within the 
10 
sci era (FIG. 7B). There also was some sulforhodamine depos-
ited on the tissue surface. Similar results were obtained for 15 
experiments conducted using bovine serum albumin-coated 
microneedles (data not shown). 
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spaced approximately 4 mm apart in a radial pattern around 
the center of the cornea. The pupil diameter was measured 
over time to assess pilocarpine-induced constriction. As a 
negative control, pupil size of the untreated eye was measured 
at the same time points. As positive controls, a 50 µI drop of 
0.01 % (w/v) pilocarpine solution was topically applied to the 
eye (5 µg pilocarpine) and a 50 µI drop of 1% (w/v) oph-
thalmic pilocarpine solution (500 µg pilocarpine) was topi-
cally applied to the eye. 
In the negative control, pupil size remained unchanged 
over the 30 min observation period. In contrast, microneedle 
delivery of pilocarpine caused pupil constriction from 8 mm 
to 5.5 mm diameter within 15 min. Topical delivery of an 
almost identical dose of pilocarpine caused pupil constriction 
to just 7 mm with slower kinetics. As a positive control, 
topical delivery of a pilocarpine dose more than 90 times 
greater than the microneedle dose caused pupil constriction to 
4 mm with similar kinetics. AN OVA analysis showed that the 
changes in pupil diameter over time were all different from 
The microneedles were examined using brightfieldmicros-
copy to identify any mechanical defects after insertion. Nei-
ther needle breakage nor bending were detected, which sug-
gests that the microneedles were sufficiently strong and sharp 
to penetrate into rigid scleral and corneal tissues. The bottom 
half of the microneedle shafts, however, generally showed 
evidence of residual coating, which likely was due to the 
incomplete microneedle insertion into the tissue. 
20 each other among the four experimental conditions 




Bioavailability ofln Vivo Drug Delivery to Rabbit 
Cornea 
In Vivo Drug Delivery to Rabbit Cornea A one-compartment pharmacokinetic analysis of the in 
30 vivo fluorescein delivery data obtained in Example 3 was 
conducted to determine the total dose of fluorescein delivered New Zealand white rabbits were anesthetized using intra-
muscular injection ofketamine and xylazine. Then, the fluo-
rescein-coated microneedles from Example 1 were inserted 
into the upper region of the cornea and left within the tissue 
for two minutes. After removal of the microneedle, fluores- 35 
cein concentration in the anterior segment of the eye was 
measured by spectrofluorometry for ~24 h (n=4). 
To facilitate imaging and fluorometric analysis, fluorescein 
was delivered to the cornea, rather than the sclera, and moni-
tored fluorescein concentration in the anterior of the rabbit 40 
eye for 24 hours after insertion of a microneedle coated with 
280 ng fluorescein. As shown in FIGS. SA-B, fluorescein 
concentration was measured over time as a function of the 
distance along the visual axis in the anterior segment of the 
eye from the cornea to lens. Prior to microneedle insertion, 45 
only small amounts of background fluorescence were 
detected in the aqueous humor. At the first measurement made 
just 1 min after microneedle insertion, a sharp increase of 
intraocular fluorescein concentration was observed. FIG. SA 
shows that the measured fluorescein concentration in the 50 
into the eye after microneedle treatment. Using the anterior 
segment as the compartment in a one-compartment model, a 
mass balance on fluorescein in the aqueous humor of the 
rabbit eye was performed 
(EQ.1) 
where M,n is the fluorescein mass inflow rate from the cornea, 
Mout is the fluorescein outflow rate via aqueous humor drain-
age, and Mace is the fluorescein accumulation rate in the 
aqueous humor. This approach neglects fluorescein outflow 
by routes other than aqueous humor drainage, such as uptake 
into the lens. 
The fluorescein outflow rate can be calculated as: 
(EQ.2) 
where Cft is the fluorescein concentration in the aqueous 
humor, which is assumed to be spatially uniform (which is an 
imperfect assumption) and therefore equal to the average 
experimental measurement, and v aq is the aqueous humor 
volumetric flow rate, which is reported as 4.2-4.5 µI/min in 
the rabbit eye (see Patt & Wissman Physiology of the Eye. An 
anterior segment further increased, reaching a peak after 3 
hours, and then gradually decreased to background levels 
within 24 hours. These results suggest that the fluorescein 
coating dissolved off the microneedle (within seconds) into a 
depot formed within the cornea, which steadily released fluo-
rescein into the anterior segment of the rabbit eye for hours. 
55 Introduction to the Vegataitive Functions, 2nd ed (1992)). 
For comparison, a control experiment was performed using 
a conventional topical application with a 10-fold larger fluo-
rescein dose (i.e., 2.8 µg), and similarly measured the fluo-
rescein concentration in the eye over time. As shown in FIG. 60 
SB, there was delivery of only very low levels of fluorescein 
to the aqueous humor after topical delivery. 
The delivery of a bioactive drug was measured by individu-
ally inserting five pilocarpine-coated microneedles (1.1±0.5 
µg pilocarpine per microneedle for a total of 5.5 µg pilo- 65 
carpine) half way into the rabbit cornea under anesthesia and 
then removed after 20 seconds. The microneedles were each 
The fluorescein accumulation rate can be estimated as 
(EQ. 3) 
where !1Cf, is the change of fluorescein concentration in the 
aqueous humor between two measurements; V aq is the aque-
ous humor volume, which is approximately 0.3 ml in the 
rabbit eye; (See Conrad & Robinson,J Pharm Sci 66:219-224 
(1977) ). and /1t is the time between measurements. 
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By substituting EQ. 2 and EQ. 3 into EQ. 1, the fluorescein 
mass inflow rate is estimated as 
(EQ. 4) 5 
18 
whether a hole remained in the cornea at the site of insertion 
and (ii) whether any inflammatory response was present, as 
indicated by the occurrence of anterior chamber cells or flare 
(as described by Shah et al., Br J Ophthalmol 75:348-52 
(1991) ). Before each examination, a drop of fluorescein solu-
tion was applied topically to stain sites of corneal damage, in 
order to identify the insertion hole. 
A small abrasion was identified at the site of microneedle 
insertion; however, evidence of the insertion wound was no 
and the total amount of fluorescein entering the aqueous 
humor (M,n.totals ) is equal to 
l 
Min,total = .L Minn !J.tn 
(EQ. 5) 
10 longer visible after 3 hours, indicating a resealing of the hole, 
perhaps by epithelial cell migration and restitution (as 
described by Coke & Podolsky, Baillieres Clin Gastroenterol 
10:393-405 (1996)). There was no evidence of an inflamma-
15 tory response at any time point as shown by a lack of anterior 
chamber cells and flare responses. 
where i is the number of measurement points and n is the 
corresponding measurement point number. In this endpoint 
calculation, the total amount of fluorescein that entered the 
aqueous humor equals the total amount that left the aqueous 20 
humor and the accumulation terms goes to zero. Bioavailabil-
ity was determined as the ratio of the total amount of fluores-
cein entering the aqueous humor and the amount of fluores-
cein coated onto the microneedle. 
The total amount of fluorescein delivered into the aqueous 25 
humor was calculated to be 196±15 ng, or approximately 
69% of the dose of fluorescein coated on the microneedle. A 
similar pharmacokinetic analysis of the data for topically 
applied fluorescein yielded a bioavailability of just 1 %. 
EXAMPLE 6 
Hollow Glass Microneedles 
Single, hollow, glass microneedles were fabricated using a 
micropipette puller as previously described by McAllister, et 
al., Proc. Nat'! Acad. Sci. U.S.A. 100:13755-60 (2003). Fire-
polished borosilicate glass pipettes (outer diameter of 1.5 
mm, inner diameter of0.86 mm, B150-86-15, Sutter Instru-
ment, Novato, Calif.) were pulled using a micropipette puller 
(P-97, Sutter Instrument) and detached into two microneedles 
at desired settings. These blunt-tip microneedles then were 
To validate these calculations, in vitro experiments were 
conducted. The amount of fluorescein delivered into rabbit 
cadaver cornea from fluorescein-coated microneedles and the 
amount of fluorescein remaining on the needle after insertion 
were measured. An average of 74±27% of the fluorescein 
coated onto the microneedle was delivered into the cornea in 
vitro, similar to the result obtained from the in vivo pharma-
cokinetic analysis. 
30 beveled at a setting of20 degree tip angle using a glass grinder 
(BV-10, Sutter Instrument) and then cleaned sequentially in a 
chromic acid bath, DI water bath, and acetone bath for 15 
seconds each. The glass microneedles had a tip opening of 
100 µm in length and 40 µm in diameter, and an angle of 25 
35 degrees. 
It is believed that the fluorescein was released from the 
microneedle to form a depot in the corneal tissue, which 
provided subsequent drug release with a bioavailability of 40 
approximately 70%. Thus, the microneedle delivery provided 
EXAMPLE 7 
In Vitro Drug Delivery to Human Sciera 
The single microneedles of Example 6 were inserted into 
human cadaver sclera ata constant pressure (5, 10, 15, 20, and 
25 psi) and used to deliver a sulforhodamine solution. Sulfor-
hodamine (558 Da; Molecular Probes, Eugene, Oreg.), which 
a 70-fold increase in bioavailability relative to topical appli-
cation. It is believed that the remaining fluorescein either 
remained adherent to the microneedle or might have been 
washed away by the tear fluid. 45 serves as a model drug and a visual marker for fluid flow, was 
added to phosphate buffered saline (PBS) to make a 1xl0-3 M 
sulforhodamine solution and was loaded into a glass syringe 
fluidly connected to the glass microneedle as described in 
A similar analysis of pilocarpine bioavailability was con-
ducted. Topical delivery of 5 .0 µg of pilocarpine resulted in 
pupil constriction of 1 mm and topical delivery of 500 µg of 
pilocarpine resulted in pupil constriction of 4 mm. Micron-
eedle delivery 5 .5 µg of pilocarpine resulted in pupil constric- 50 
tion of 2.5 mm, or the equivalent of a topical delivery of 
approximately 250 µg of pilocarpine (assuming a linear dose-
response relationship and carrying out linear interpolation of 
the two topical delivery doses). Thus, the microneedle deliv-
ery ofpilocarpine provided a 45-fold increase in pilocarpine 55 
bioavailability relative to topical administration. 
EXAMPLES 
Non-Coated Microneedle Inserted into Rabbit 
Cornea 
To assess the safety of microneedle insertion into the eye, 
the single, non-coated microneedle of Example 1 was 
inserted into the cornea ofan anesthetized rabbit in vivo. At 0, 
1, 2, 3, 4, and 24 hours after insertion, the eye was examined 
by a clinical opthalmologist using a slit lamp to identify (i) 
Wang, et al., Diabetes Tech & Ther 7: 131-41 (2005). The 
microneedles were initially inserted into the tissue at a depth 
of 700-1080 µm, and retracted out of the tissue in increments 
of 60 µm during the solution injection. The volumetric deliv-
ery of sulforhodamine solution was monitored by the move-
ment of the gas-fluid meniscus in the glass syringe, and the 
differences were recorded between each retraction. The infu-
sion was immediately stopped when a retraction caused leak-
age of sulforhodamine solution to be first seen on the surface 
of the tissue. 
Generally, the distribution of the sulforhodamine solution 
60 appeared in a circular shape, with a diameter ranging from 
millimeters up to one centimeter, depending on infusion con-
ditions (data not shown). The insertion of a single micron-
eedle 720 µm into the middle region of a scleral piece, and the 
retraction 200 µm to infuse sulforhodamine solution into the 
65 tissue resulted in an insertion pathway with a depth of300 µm 
and an insertion gap having the shape of the needle tip. The 
difference between the needle penetration depth and the 
US 7,918,814 B2 
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insertion depth that occurred is believed to have been caused 
by elastic deformation of the tissue during insertion. 
In the human eye, the sclera is relatively thick near the 
limbus (0.53±0.14 mm); it thins at the equator (0.39±0.17 
mm) and becomes substantially thicker near the optic nerve 
(0.9 to 1.0 mm) (Olsen, et al., Am J Opthalm 125:237-41 
(1998) ). To examine the effect of scleral thickness on volume 
delivery, the sclera was divided into 3 different regions 
around the globe: front (near the limbus), middle (at the 
equator), and back (near the optic nerve). The microneedles 
were inserted into each region of the sclera at a controlled 
depth (720-1080 µm), and then partially retracted. Each 
retraction displacement was 60 µm and lasted 3 minutes. 
Since the scleral tissue at the equator is thinner compared to 
that near the limbus and the optic nerve, typically less retrac-
tion (209±92 µm) in the middle region was used comparing to 
that in the front (287±182 µm) and in the back regions 
(262±145 µm). 
Essentially no solution was delivered into the tissue after 
the initial insertion in all experiments. Upon further retraction 
from 200 to 300 µm the delivery was achieved at volumes of 
10 to 15 µL from individual microneedles. Not wishing to be 
bound by any theory, it is believed that these observations can 
be explained by the elastic nature of the scleral fibers. The 
scleral fibers are known to be elastic (Bourges, et al., Invest 
Opthalm & Visual Sci 44:3562-69 (2003)), and the elastic 
system appears to be largely confined to the deeper layers in 
the sclera (Raspanti, et al., J Anatomy 181(Part 2): 181-87 
(1992)), which could cause the zero volumetric delivery after 
the initial insertion. After the needle penetrated into inner 
portion of the sclera, the fibers were deformed due to the 
compression of needle tip and blocked the needle tip opening, 
thereby stopping the solution flow. As the microneedle was 
retracted back into the upper layer, where the fibers were less 
elastic, opening spaces between the needle and collagen 
fibers began to form, allowing the solution to spread within 
the tissue. 
EXAMPLES 
In Vitro Delivery ofNanoparticles & Microparticles 
to Human Sciera 
20 
The nanoparticles were successfully delivered within the 
tissue; however, unlike the results from sulforhodamine infu-
sion experiments, the nanoparticles did not spread widely 
within the tissue. Concentrated particle regions were evident 
around the microneedle insertion gap, which suggested that 
the particles filled the spaces between collagen fibers. The 
amount of nanoparticles infused into the scleral tissue 
increased as the concentration of particles in the donor solu-
tion increased in each region of the sclera. At lower nano-
lO sphere concentrations, the distribution of the particles 
appeared to be localized around the needle insertion site. At 
the higher concentrations, the particles spread further away 
from the insertion site. In each experiment, a large majority of 
15 
the suspension was delivered into the sclera with only a tiny 
amount, up to a couple of micro liters, leaking onto the scleral 
surface. 
The microparticles were not delivered to the tissue in any 
significant number in this instance. The microparticles 
20 appeared to clog the tip of the hollow microneedles, though it 
is believed that the presence of scleral tissue played a critical 
role in blocking flow. The collagen fibers in the human sclera 
are reported to vary from 160 nm to 220 nm in diameters 
(Raspanti, et al., J. Anatomy 181(Part 2): 181-87 (1992)), and 
25 their center-to-center spacing varies between 250 nm and 280 
nm (Edwards & Prausnitz, AIChE 44:214-25 (1998)), corre-
sponding to an edge-to-edge spacing of 410 nm to 500 nm. 
Accordingly, it is believed that the nanometer-scale spacing 
between scleral collagen fibers might serve as a barrier during 
30 microparticle delivery, thereby restricting the ability oflarge-
sized microspheres to pass into the scleral tissue. The non-
collagenous proteins also may play a role in controlling trans-
port in the sci era. These proteins make up 10% of the scleral 
dry weight (Fattand & Wissman, Physiology of the Eye. An 
35 Introduction to the Vegatatve Function, Buterworth-Heine-
mann, Boston, Mass. (1992)), and some of them are associ-
ated with glycosaminoglycans (GAGs) and together form 
proteoglycan complexes (the GAGs form side chains that are 
chemically linked to a core protein) (Edwards & Prausnitz 
40 (1998)). The junctions of these proteoglycan complexes 
therefore also may play an important role in microparticle 
delivery. 
EXAMPLE 9 
Experiments were conducted to evaluate the ability of the 45 
hollow microneedles of Example 6 to deliver nanoparticles or 
microparticles into the sclera. Each microneedle was pre-
loaded with 20 µl of the nanosphere or microsphere suspen-
sion, inserted into each region on the sclera, and delivered into 
the tissue using the insertion and retraction procedures of 50 
Example 7. 
In Vitro Drug Delivery of Microparticles with 
Collagenase or Hyaluronidase 
Two types of experiments were performed to examine the 
effect ofhyaluronidase, an enzyme known to break down the 
GAGs in the scleral extracellular matrixes, or collagenase 
type I, which is known to break down type I collagen fibers, 
on scleral delivery using the hollow microneedles ofExample 
6. In one experiment, the scleral tissue was soaked in a 200 
U/ml hyaluronidase solution (Vitrase, 200 U/ml, ISTA Phar-
maceuticals, Irvine, Calif.) or a collagenase type I solution for 
1 hour prior to microneedle injection and later infusion 
experiments were performed. In the second experiment, a 
hyluronidase solution or a collagenase type I solution was 
mixed with the injectable solution and delivered into the 
sclera by the hollow microneedles. 
Nanospheres comprised Nile Red encapsulated within 
poly-lactic acid (PLA) (effective diameter of 278±13 nm) 
particles (courtesy of Dr. Uday Kompella, University of 
Nebraska). PBS solutions of the nanoparticles were prepared 55 
with solid contents of0.5, 1, 5, and lOwt %, vortexed to break 
up aggregates, and delivered into the sclera at 15 psi. 
PBS solutions containing solid latex, fluorescein-labeled 
microspheres (1.0 micron in diameter, Polysciences Inc., 
Warrington, Pa.) were prepared with solid contents of 0.3, 60 
1.3, and 2.6 wt % for infusion into sclera. A drop of 5 µl 
polyoxyethylenesorbitan monooleate (Tween 80, Sigma 
Chemical Co., St. Louis, Mo.) was added to each ml solution 
to reduce the surface tension and enhance the microparticle 
stability within the suspension. The mixture was vortexed and 65 
ultrasonicated to ensure the microspheres were suspended 
without aggregating within the solution. 
A significantly larger dose of micro spheres was delivered 
into each region of the scleral tissue that was soaked in the 
hyaluronidase solution prior to the infusion experiment. The 
same effect also took place in the hyaluronidase-mixed infu-
sion tests, thereby indicating that the effect ofhyaluronidase 
is extremely rapid. Accordingly, it is believed that by breaking 
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down the ground substance in the sclera matrix larger par-
ticles, such as microparticles, can be delivered into the scleral 
tissue. 
A significantly larger dose of micro spheres also was deliv-
ered into each region of the scleral tissue with the collagenase 
experiments (data not shown). It is believed that the tight 
architecture of the collagen fibers served as a critical barrier in 
micron-sized particle delivery. 
Publications cited herein and the materials for which they 
are cited are specifically incorporated by reference. Modifi- 10 
cations and variations of the methods and devices described 
herein will be obvious to those skilled in the art from the 
foregoing detailed description. Such modifications and varia-




1. A method of administering a drug to an eye of a patient, 
comprising: 
inserting at least one hollow microneedle into the sclera or 
corneal stroma of the eye without penetrating across the 
sclera or corneal stroma; and 
20 
infusing a fluid drug formulation through the at least one 
hollow microneedle and into the sclera or cornea, 25 
wherein the fluid drug formulation comprises a drug. 
2. The method of claim 1, further comprising, after the 
insertion step and before and/or during the step of infusing, 
partially retracting the at least one hollow microneedle from 
the sclera or corneal stroma. 
3. The method of claim 2, wherein the step of infusing is 
performed after the step of retracting the at least one micron-
eedle out of the sclera or corneal stroma. 
30 
4. The method of claim 1, wherein the step of inserting 
further comprises substantially simultaneously inserting a 35 
second hollow microneedle into the sclera or corneal stroma 
22 
13. The method of claim 2, wherein the steps of inserting 
and retracting the at least one hollow microneedle form a 
pocket in the sclera or corneal stroma. 
14. The method of claim 1, wherein the step of infusing 
creates a drug depot in the sclera or corneal stroma for sus-
tained release of the drug from the drug depot afterthe step of 
infusion is completed. 
15. A method ofadministering a drug to an eye ofa patient, 
comprising: 
inserting at least one solid microneedle into the sclera or 
corneal stroma of the eye without penetrating across the 
sclera or corneal stroma, wherein the at least one solid 
microneedle comprises a first quantity of a drug formu-
lation and the step of inserting causes the at least one 
solid microneedle to form a pocket in the sclera or cor-
neal stroma; and 
releasing at least part of the first quantity of the drug for-
mulation into the pocket to form a drug depot in the 
sclera or corneal stroma, whereby a drug in the drug 
formulation subsequently is released from the drug 
depot. 
16. The method of claim 15, wherein the step of inserting 
further comprises substantially simultaneously inserting a 
second solid microneedle into the sclera or corneal stroma 
without penetrating across the sclera or corneal stroma, the 
second solid microneedle comprising a second quantity of the 
drug formulation, and wherein the step of inserting causes the 
second solid microneedle to form a second pocket in the 
sclera or corneal stroma, 
wherein the step of releasing further comprises releasing 
the second quantity of the drug formulation into the 
second pocket to form a second drug depot in the sclera 
or corneal stroma, whereby subsequently the drug is 
released from the second drug depot into the eye, 
wherein the at least one solid microneedle and the second 
solid microneedle are part of a device which comprises 
an array of two or more microneedles. without penetrating across the sclera or corneal stroma, and 
the step of infusing further comprises infusing the fluid drug 
formulation through the second hollow microneedle and into 
the sclera or corneal stroma, wherein the at least one hollow 
microneedle and the second hollow microneedle are part of a 
device which comprises an array of two or more micron-
eedles. 
17. The method of claim 15, further comprising completely 
withdrawing the at least one solid microneedle from the sclera 
40 or corneal stroma after the step of inserting, wherein the drug 
depot provides sustained release of the drug after the at least 
one solid microneedle has been completely withdrawn. 
5. The method of claim 1, wherein the fluid drug formula-
tion comprises a suspension of microparticles or nanopar-
ticles for controlled release of the drug. 
18. The method of claim 15, wherein the at least one solid 
microneedle comprises a solid or semi-solid coating which 
45 comprises the drug formulation. 
6. The method of claim 1, wherein the at least one hollow 
microneedle is inserted into the surface of the sclera or cor-
neal stroma at an angle of about 90 degrees. 
7. The method of claim 1, wherein the at least one hollow 50 
microneedle comprises a metal. 
8. The method of claim 1, wherein the at least one hollow 
microneedle is rotated or vibrated during the step of inserting. 
9. The method of claim 1, wherein the step of infusing 
comprises driving the fluid drug formulation using a pressure 55 
gradient or an electric field. 
19. The method of claim 18, wherein the step of releasing 
comprises at least partially dissolving the coating off of the at 
least one solid microneedle into fluids present in the sclera or 
corneal stroma. 
20. The method of claim 15, wherein the step of releasing 
comprises breaking or dissolving all or part of the at least one 
solid microneedle, which includes the drug formulation, off 
of a base to which the at least one solid microneedle is con-
nected prior to said breaking or dissolving. 
21. The method of claim 15, wherein the drug formulation 
comprises microparticles or nanoparticles which comprise a 
drug for controlled release. 10. The method of claim 1, for use in the treatment of 
uveitis, glaucoma, diabetic macular edema, age-related 
macular degeneration, corneal infection, or cytomegalovirus 
retinitis. 
22. The method of claim 15, wherein the at least one solid 
microneedle is inserted into the surface of the sclera or cor-
60 neal stroma at an angle of about 90 degrees. 
11. The method of claim 1, wherein the fluid drug formu-
lation further comprises an agent effective to degrade col-
lagen or glycosaminoglycan fibers in the sclera or corneal 
stroma. 
12. The method of claim 11, wherein the agent comprises 65 
an enzyme selected from the group consisting of a hyalu-
ronidase, a collagenase, or a combination thereof. 
23. The method of claim 15, wherein the at least one solid 
microneedle comprises a metal. 
24. The method of claim 15, wherein the at least one solid 
microneedle comprises a polymer. 
25. The method of claim 15, wherein the at least one solid 
microneedle is rotated or vibrated during the step of inserting 
or during the step of releasing. 
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26. The method of claim 15, further comprising driving the 
drug into or through the sclera or corneal stroma using an 
electric field or acoustic energy. 
27. The method of claim 15, for use in the treatment of 
uveitis, glaucoma, diabetic macular edema, age-related 
macular degeneration, corneal infection, or cytomegalovirus 
retinitis. 
28. The method of claim 1or15, wherein the drug from the 
drug depot is delivered to choroidal or retinal tissues. 
29. The method of claim 1 or 15, wherein the drug is 10 
delivered to the ciliary body or the trabecular meshwork. 
30. The method of claim 1 or 15, wherein the drug is 
delivered to the aqueous humor or the vitreous humor. 
31. A method of extraction from a tissue of the eye com-
15 
prising: 
inserting at least one microneedle into the sclera or corneal 
stroma, without penetrating across the sclera or corneal 
stroma; and 
withdrawing a biological fluid, tissue, or molecule sample 20 
from the sclera or corneal stroma with the at least one 
microneedle. 
24 
40. The device of claim 32, wherein the two or more 
microneedles comprise a metal. 
41. The device of claim 32, wherein the two or more 
microneedles comprise a polymer. 
42. The device of claim 32, wherein the two or more 
microneedles extend from the base at an angle of about 90 
degrees to provide approximately perpendicular insertion of 
the microneedles into the surface of the sclera or corneal 
stroma. 
43. The device of claim 32, wherein the base has either a 
fixed radius of curvature substantially the same as the radius 
of curvature of the surface of a sclera or corneal stroma, or is 
elastically deformable to fit the radius of curvature of the 
surface of a sclera or corneal stroma. 
44. The device of claim 32, wherein the two or more 
microneedles are hollow. 
45. The device of claim 44, wherein the means for depos-
iting comprises a fluid drug formulation, a source reservoir 
for the fluid drug formulation, and an infusion means for 
driving the fluid drug formulation from the source reservoir 
into the pocket. 
46. The device of claim 45, wherein the infusion means 
comprises a pump or syringe. 
32. A microneedle device for delivery of a drug to the eye 
comprising: 
an array of two or more microneedles extending from a 
base; 
47. The device of claim 45, wherein the fluid drug formu-
25 lation further comprises an agent effective to degrade col-
lagen or glycosaminoglycan fibers in the sclera or corneal 
means for controllably inserting the two or more micron-
eedles into the sclera or corneal stroma without penetrat-
ing across the sclera or corneal stroma; and 
means for depositing a drug formulation in the sclera or 30 
corneal stroma to form a drug depot for subsequent 
release to an ocular tissue. 
33. The device of claim 32, wherein the drug depot pro-
vides extended or sustained release of a drug after the two or 
more microneedles have been completely withdrawn from 35 
the sclera or corneal stroma. 
34. The device of claim 33, wherein the drug formulation 
comprises microparticles or nanoparticles which provide 
controlled release of the drug. 
35. The device of claim 32, wherein the two or more 40 
microneedles are solid. 
36. The device of claim 35, wherein the means for depos-
iting comprises a coating on the two or more microneedles, 
wherein the coating comprises the drug formulation. 
37. The device of claim 36, wherein the coating is solid or 45 
semi-solid. 
38. The device of claim 37, wherein the coating is at least 
partially soluble in fluids present in the sclera or corneal 
stroma. 
39. The device of claim32, wherein all or part of the two or 50 
more microneedles are adapted to break or dissolve off of the 
base in the sclera or cornea. 
stroma. 
48. The device of claim 47, wherein the agent comprises an 
enzyme selected from the group consisting of a hyalu-
ronidase, a collagenase, or a combination thereof. 
49. The device of claim 45, wherein the fluid drug formu-
lation comprises a suspension of microparticles or nanopar-
ticles which comprise a drug for controlled release. 
50. The device of claim 32, wherein the portion of the 
microneedles that is designed to insert into the sclera or 
corneal stoma has a maximum cross-sectional width or diam-
eter between 50 microns and 400 microns. 
51. The device of claim 32, wherein the portion of the 
microneedles that is designed to insert into the sclera or 
corneal stoma has length between 50 microns and 1000 
microns. 
52. A microneedle device for delivery of a drug to the eye 
comprising: 
at least one solid microneedle extending from a base; 
means for controllably inserting the at least one solid 
microneedle into the sclera or corneal stroma without 
penetrating across the sclera or corneal stroma; and 
a drug formulation which comprises a drug, wherein the 
device is adapted to deposit the drug formulation into the 
sclera or corneal stroma to form a drug depot for con-
trolled release of the drug to an ocular tissue. 
* * * * * 
